No Data
No Data
Biogen: A Balanced View Amidst Setbacks and Alzheimer's Drug Potential
Sector Update: Health Care Stocks Mixed in Late Afternoon Trading
Health care stocks were mixed late Thursday afternoon, with the NYSE Health Care Index decreasing 0.1% and the Health Care Select Sector SPDR Fund (XLV) up 0.1%. The iShares Biotechnology ETF (IBB) wa
Biogen and Ionis Pharma Shares Slide as They End Development of ALS Treatment
By Ciara Linnane An early-stage trial failed to slow disease process The stocks of Biogen Inc. and Ionis Pharmaceuticals Inc. were lower Thursday, after the partners said they were terminating devel
US Equity Indexes Trade Mixed as Investors Weigh Macro Data; Dow Touches Record High
US equity indexes traded mixed after midday on Thursday, with the Dow Jones Industrial Average touching the 40,000 mark for the first time, as a smaller-than-expected decline in jobless claims coincid
Biogen CEO Looks for Small Deals While Alzheimer's Drug Ramps Up
Biogen Also Drops Collaboration With Ionis on Angelman Syndrome Candidate
No Data